Eschenburg Georg, Stermann Alexander, Preissner Robert, Meyer Hellmuth-Alexander, Lode Holger N
Experimental Oncology Group, Department of Pediatrics, Charité-University Medicine Berlin, 13353 Berlin, Germany.
Clin Dev Immunol. 2010;2010:169484. doi: 10.1155/2010/169484. Epub 2010 Dec 16.
Cancer is one of the most challenging diseases of today. Optimization of standard treatment protocols consisting of the main columns of chemo- and radiotherapy followed or preceded by surgical intervention is often limited by toxic side effects and induction of concomitant malignancies and/or development of resistant mechanisms. This requires the development of therapeutic strategies which are as effective as standard therapies but permit the patients a life without severe negative side effects. Along this line, the development of immunotherapy in general and the innovative concept of DNA vaccination in particular may provide a venue to achieve this goal. Using the patient's own immune system by activation of humoral and cellular immune responses to target the cancer cells has shown first promising results in clinical trials and may allow reduced toxicity standard therapy regimen in the future. The main challenge of this concept is to transfer the plethora of convincing preclinical and early clinical results to an effective treatment of patients.
癌症是当今最具挑战性的疾病之一。由化疗和放疗这两大主要支柱组成、并在手术干预之前或之后进行的标准治疗方案的优化，常常受到毒副作用以及伴随恶性肿瘤的诱发和/或耐药机制形成的限制。这就需要开发出与标准疗法同样有效，但能让患者过上没有严重负面副作用生活的治疗策略。沿着这一思路，总体而言免疫疗法的发展，尤其是DNA疫苗接种这一创新概念，可能为实现这一目标提供一条途径。通过激活体液免疫和细胞免疫反应来利用患者自身的免疫系统靶向癌细胞，已在临床试验中显示出初步的喜人成果，并且未来可能会使标准治疗方案的毒性降低。这一概念的主要挑战在于将大量令人信服的临床前和早期临床结果转化为对患者的有效治疗。
